Stem Cell Therapy

What is Stem Cell Therapy?

Stem cell therapy is a form of regenerative medicine that uses stem cells — undifferentiated cells capable of self-renewal and differentiation into specialised cell types — to repair, replace, or regenerate damaged tissues and organs. Stem cells can be classified as embryonic stem cells (ESCs), adult/somatic stem cells (e.g., hematopoietic stem cells from bone marrow), induced pluripotent stem cells (iPSCs), and cord blood stem cells.

In India, stem cell research and therapy are governed by the National Guidelines for Stem Cell Research, jointly formulated by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT). The latest version — the National Guidelines for Stem Cell Research 2025 — was released to strengthen regulation amid growing concerns over unproven and unregulated stem cell clinics operating in the country.

The only stem cell therapy established as Standard of Care in India is hematopoietic stem cell transplantation (HSCT) for specific blood disorders, cancers, and immunodeficiency conditions. All other stem cell therapies are considered investigational and must be conducted through approved clinical trials with CDSCO (Central Drugs Standard Control Organization) and ethics committee approval.

Types of Stem Cells

Embryonic Stem Cells (ESCs): Derived from the inner cell mass of blastocysts (3-5 day old embryos); are pluripotent — can differentiate into any cell type. Ethically controversial due to embryo destruction. Adult/Somatic Stem Cells: Found in bone marrow, blood, skin, and other tissues; generally multipotent (limited differentiation). Hematopoietic stem cells (HSCs) from bone marrow are the most clinically used. Induced Pluripotent Stem Cells (iPSCs): Adult cells reprogrammed to an embryonic-like state using specific transcription factors (Oct4, Sox2, Klf4, c-Myc); discovered by Shinya Yamanaka in 2006 (Nobel Prize 2012). Avoids ethical concerns of ESCs. Cord Blood Stem Cells: Collected from umbilical cord blood at birth; rich in HSCs; can be stored in cord blood banks for future use.

Potency hierarchy: Totipotent (zygote — can form entire organism) > Pluripotent (ESCs, iPSCs — all cell types except placenta) > Multipotent (adult stem cells — limited cell types) > Unipotent (only one cell type).

Key Features

Current Status / Latest Data

• National Guidelines 2025: ICMR and DBT released updated National Guidelines for Stem Cell Research 2025, tightening oversight over both research and clinical applications.
• Supreme Court Directive (March 2026): NMC issued an advisory directing medical colleges to comply with Supreme Court directions — stem cell therapy in routine practice is permitted only for diseases listed by the Health Ministry; all other use must be through approved clinical trials.
• Unproven Therapies Concern: India has seen a surge in unlicensed stem cell clinics offering unproven treatments for conditions like autism, cerebral palsy, and spinal cord injury, prompting regulatory crackdown.
• MSC Transplantation: The ICMR's evidence-based review states that mesenchymal stem cell (MSC) transplantation is not recommended for any disease condition as Standard of Care.
• HSCT in India: India performs approximately 3,000-4,000 HSCTs per year across major centres, primarily for blood cancers (leukaemia, lymphoma) and thalassemia.
• Cord Blood Banking: Both public and private cord blood banks operate in India, with the Jeevan Cord Blood Bank being one of the largest public banks.
• Ethical Framework: Informed consent mandatory; commercial exploitation of stem cells prohibited; embryonic research restricted to surplus IVF embryos up to 14 days.

UPSC Exam Corner

Prelims: Key Facts

• Stem cell types: ESC, Adult, iPSC, Cord Blood
• Only approved therapy: Hematopoietic Stem Cell Transplantation (HSCT)
• Guidelines: National Guidelines for Stem Cell Research 2025 by ICMR + DBT
• Clinical trials regulated by: CDSCO (under Drugs and Cosmetics Act)
• iPSCs: discovered by Shinya Yamanaka (Nobel Prize 2012); adult cells reprogrammed to pluripotent state
• Embryonic stem cell research: permitted on surplus IVF embryos up to 14 days
• MSC therapy: not recommended as Standard of Care for any disease (ICMR)
• Potency hierarchy: Totipotent > Pluripotent > Multipotent > Unipotent
• Cord blood banking: both public and private banks operate in India
• Embryonic research limit: surplus IVF embryos up to 14 days only
• India performs ~3,000-4,000 HSCTs per year (blood cancers, thalassemia)
• Commercial exploitation of stem cells: prohibited under guidelines

Mains: Probable Themes

1. "Discuss the ethical and regulatory challenges of stem cell therapy in India." — Unproven clinics, patient exploitation, informed consent
2. "Examine the regulatory framework governing stem cell research in India. Is it adequate?" — ICMR-DBT guidelines, CDSCO role, enforcement gaps
3. "Evaluate the potential of stem cell therapy in addressing genetic disorders like thalassemia and sickle cell disease in India."
4. "The proliferation of unregulated stem cell clinics in India demands urgent legislative action. Discuss."
5. "Compare India's approach to stem cell regulation with the frameworks in the USA and EU."
6. "Evaluate the potential of induced pluripotent stem cells (iPSCs) in advancing personalised medicine in India."

Sources: ICMR — Stem Cell Guidelines | Stem Cell Care India — Guidelines 2025 | Medical Dialogues — NMC Advisory 2026 | Oxford Academic — Unproven Stem Cell Therapies India